Morgan Stanley Maintains Underweight on Innoviva, Raises Price Target to $12
Morgan Stanley maintains Innoviva (NASDAQ:INVA) with a Underweight and raises the price target from $10 to $12.
EF Hutton Initiates Coverage On Innoviva with Buy Rating, Announces Price Target of $28
EF Hutton analyst Constantine Davides initiates coverage on Innoviva (NASDAQ:INVA) with a Buy rating and announces Price Target of $28.
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours:
Innoviva Q3 EPS $0.90 Up From $0.26 YoY
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.90 per share. This is a 246.15 percent increase over earnings of $0.26 per share from the same period last year.
The Daily Biotech Pulse: AbbVie’s Migraine Drug OK’d By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 28)
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer’s Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 27)